Analyst Ratings For Avadel Pharmaceuticals PLC (NASDAQ:AVDL)
Today, Avadel Pharmaceuticals PLC (NASDAQ:AVDL) stock was downgraded by LADENBURG THALM/SH SH from Buy to Neutral.
There are 4 Hold Ratings, no Strong Buy Ratings, no Sell Ratings, no Buy Ratings on the stock.
The current consensus rating on Avadel Pharmaceuticals PLC (NASDAQ:AVDL) is Hold with a consensus target price of $8.00 per share, a potential 216.21% upside.
Some recent analyst ratings include
- 2/8/2019-Avadel Pharmaceuticals PLC (NASDAQ:AVDL) gets downgraded to Neutral by LADENBURG THALM/SH SH
- 11/6/2018-Avadel Pharmaceuticals PLC (NASDAQ:AVDL) gets downgraded to Hold by Laidlaw with a price target of $6.00
- 8/7/2018-Avadel Pharmaceuticals PLC (NASDAQ:AVDL) gets downgraded to Market Perform by JMP Securities
- 8/7/2018-Avadel Pharmaceuticals PLC (NASDAQ:AVDL) gets downgraded to Hold by SunTrust Banks
- 9/7/2017-Avadel Pharmaceuticals PLC (NASDAQ:AVDL) had its Buy rating reiterated by Langenberg & Company with a $30.00 price target
- On 12/14/2018 Sandra L. Hatten, Insider, sold 3,173 with an average share price of $2.58 per share and the total transaction amounting to $8,186.34.
- On 8/10/2018 Michael S. Anderson, CEO, sold 16,297 with an average share price of $4.91 per share and the total transaction amounting to $80,018.27.
- On 8/10/2018 Sandra L. Hatten, Insider, sold 6,290 with an average share price of $4.91 per share and the total transaction amounting to $30,883.90.
- On 6/26/2018 Michael S. Anderson, CEO, bought 2,500 with an average share price of $6.04 per share and the total transaction amounting to $15,100.00.
- On 6/25/2018 James E. Flynn, Insider, sold 114,034 with an average share price of $5.99 per share and the total transaction amounting to $683,063.66.
- On 5/24/2018 Michael S. Anderson, CEO, bought 3,000 with an average share price of $6.44 per share and the total transaction amounting to $19,320.00.
- On 12/15/2017 Craig R Stapleton, Director, bought 140,000 with an average share price of $8.67 per share and the total transaction amounting to $1,213,800.00.
About Avadel Pharmaceuticals PLC (NASDAQ:AVDL)
Avadel Pharmaceuticals plc develops and commercializes pharmaceutical products primarily for treating urology and sleep medicines in the United States, France, and Ireland. Its commercial products that are used in the hospital setting include Bloxiverz, a drug used in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; Vazculep, a phenylephrine hydrochloride injection that is used for the treatment of hypotension occurring in the setting of anesthesia; and Akovaz, an ephedrine sulfate injection for treating hypotension, as well as Noctiva for treating nocturia due to nocturnal polyuria. The company owns and develops drug delivery platforms, such as Micropump, a microparticulate system that allows the development of modified and/or controlled release of solid and oral dosage formulations of drugs; LiquiTime, which allows development of modified/controlled release liquid suspension formulations; Trigger Lock that allows development of abuse-resistant modified/controlled release formulations of narcotic/opioid analgesics and other drugs susceptible to abuse; and Medusa, a hydrogel depot technology that allows the development of extended/modified release of injectable dosage formulations of drugs. Its product candidates also comprise REST-ON, which is in Phase III clinical trial for the treatment of daytime sleepiness and cataplexy in patients suffering from narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. The company was founded in 1990 and is headquartered in Dublin, Ireland.
Recent Trading Activity for Avadel Pharmaceuticals PLC (NASDAQ:AVDL)
Shares of Avadel Pharmaceuticals PLC closed the previous trading session at 2,53 −0,72 22,15 % with 520000 shares trading hands.
